ft 27 may 94 technolog red white better look latest improv blood product continu seri drug advanc blood product sector use quiet backwat healthcar busi rapidli grow money spinner engin chang biotechnolog treat blood disord creat first superstar busi california amgen five year ago blood product meant substanc deriv blood would use blood transfus supplement condit haemophilia uncontrol bleed busi suffer high cost owe labori natur collect blood donor lack patent protect turn limit price period scandal contamin big pharmaceut compani bother get involv biotechnolog make possibl high volum manufactur compon blood even appear minut quantiti bodi two big sell product develop far dramat sale come erythropoietin epo hormon produc natur bodi amgen synthesis commercialis epogen epo use treat anaemia condit aris enough epo made kidney epo travel via bloodstream bone marrow stimul product red blood cell cell carri oxygen lung rest bodi 30 year patient kidney diseas receiv dialysi mechan treatment mimic much kidney dialysi machin make epo patient develop anaemia past patient receiv blood transfus expens labori procedur carri risk infect complic today shortag natur epo address directli epogen amgen say 80 per cent dialysi patient us receiv drug second new drug stimul develop white blood cell central compon bodi immun system rather red granulocyt coloni stimul factor g csf also work stimul bone marrow time produc white blood cell g csf sold amgen neupogen use treatment cancer patient chemotherapi damag bone marrow bodi defenc mechan chemotherapi patient especi vulner infect give g csf allow improv defenc infect mean chemotherapi agent use tri deal cancer epogen neupogen made complic well test techniqu genet engin scientist analys human epo identifi compon knowledg calcul shape gene trigger product epo scan thousand human gene search correct human gene identifi put ovari hamster egg ovari later releas capabl make epo divid mani time master cell bank built larg scale manufactur cell master bank nourish fluid grow secret epo fluid period remov epo extract purifi bottl amgen receiv first patent process octob 1987 less two year later us food drug administr approv use kidney patient neupogen approv fda 1991 drug among effect market today chemic ident natur product bodi natur product cannot patent cannot easili improv upon amgen protect discoveri patent manufactur method use drug patent effect enough shut competit allow high price charg one cours neupogen cost pound 800 exampl cancer patient may need sever cours pay patient far less like come back hospit treat infect white blood cell would normal fought save money hospit bed cocktail antibiot would administ combin high price potenti save buyer translat big profit amgen first three month year saw pre tax profit dollar 93 5m pound 62 3m sale dollar 345 7m success stori bare begun accord analyst stockbrok lehman brother 2000 epogen world best sell drug neupogen far behind third place combin sale dollar 5bn year roughli level uk nation health servic annual budget today success neupogen epogen attract compani research develop programm includ sandoz switzerland sign research agreement north american biotechnolog research centr terri fox laboratori vancouv systemix palo alto california one advanc research programm british biotechnolog oxford tri combin effect epogen neupogen defend bone marrow damag done first recognis chemotherapi agent kill cancer destroy cell divid chemotherapi distinguish cancer cell other divid hair cancer patient often lose hair bone marrow contain cell call stem cell divid develop rang blood cell red white platelet caus clot british biotechnolog programm develop drug temporarili switch divis stem cell chemotherapi agent leav stem cell untouch therapi finish switch rather treatment damag caus chemotherapi prophylaxi prevent effect say peter lewi director research develop british biotechnolog compani one develop stem cell protector sandoz sweden astra cell scienc california biotechnolog compani close behind pharmaceut industri know huge market tap far cri decad ago epogen neupogen found virgin market product could compet sale forc doctor accustom sell buy treatment amgen establish seri licens deal joint ventur big drug compani even though mani compani sceptic complet novel drug explain paul hooper uk market director swiss compani roch amgen joint ventur partner europ epogen anoth compani one largest us turn chanc license recognis potenti say former senior execut later felt like record compani man turn beatl make mistak seri continu next month look pain killer worldwid blood factor sale 1992 1993 dollar dollar compani brand gener amegen neupogen g csf 544 719 amgen epogen erythrpoietin 505 587 johnson amp johnson procrit eprex erythrpoietin 450 525 chugal epogin erythrpoietin 225 270 sankyo gran g csf 162 194 sankyo espo erythrpoietin 162 183 chugal neutrogin g csf 117 134 immunex leukin gm csf 26 42 green cross leukoprol csf 29 28 sandoz leucomax gm csf 7 20 sourc datamonitor